GSK3A and neoplasm: We found that phosphorylation of GSK3a was significantly higher in palbociclib treated tumours (one-cycle) compared to vehicle (p = 0.02), demonstrating an inhibitory effect on the cell cycle during the first cycle of treatment (Figure 8).